Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tesla, Inc. (TSLA) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Tesla (TSLA) trades at $330.87, up 0.7% today, amid mixed signals: technicals are bearish with support at $327 and resistance at $333, while fundamentals show elevated valuation ratios (P/E 306.37) but recent earnings beats. Revenue dipped to $94.83B in 2025, with net margin at 3.67%, as the company pivots toward AI and robotics. News highlights regulatory approval for self-driving software in Europe (Reuters, 2026-04-10) and a 315% surge in German registrations (Zacks, 2026-04-10).

Outlook: Tesla's stock faces headwinds from high valuation and slowing auto growth, but opportunities exist in AI and energy expansion. Risks include intense EV competition and execution challenges. Analysts are divided, with a consensus price target of $393.87 (40.74% buy ratings), suggesting cautious optimism if innovation delivers.